Welcome to our dedicated page for Adm Tronics news (Ticker: ADMT), a resource for investors and traders seeking the latest updates and insights on Adm Tronics stock.
ADM Tronics Unlimited, Inc. (ADMT) is a micro-cap medical device company that designs, develops, and manufactures therapeutic and diagnostic equipment at its FDA-registered facility. News coverage for this stock typically centers on quarterly and annual financial results, product development milestones, and regulatory updates.
ADM Tronics generates news through its dual business model: contract manufacturing services for medical device clients and development of proprietary technologies. The company's proprietary portfolio spans multiple medical fields including audiology, physical medicine, wound therapy, neurology, and urology. Recent product development has focused on veterinary applications, particularly ultrasound-based pain treatment technology for animal health markets.
Investors following ADMT news should expect regular earnings announcements that detail revenue from both contract services and proprietary device sales. Product launch updates and trade show presentations offer insight into commercialization progress. As a small-cap FDA-regulated company, any regulatory submissions or clearances represent material developments worth monitoring.
Bookmark this page to track ADM Tronics developments. Our platform aggregates press releases, earnings reports, and relevant industry news so you can follow this medical device manufacturer without searching multiple sources.
ADM Tronics Unlimited, Inc. (OTCQB: ADMT) reported its third fiscal quarter results for FY 2023, highlighting a net income of $155,148 for the nine months ended December 31, 2022, a turnaround from a net loss of $140,221 a year prior. Revenues surged over 31% to $3,044,838 compared to $2,322,871 for the same period in 2021. The Electronics segment alone saw a revenue increase of over 73%. For the latest quarter, ADMT also posted a net income of $93,771, contrasting a net loss of $72,393 for the same quarter last year. The company attributes its revenue growth to all three operational segments: Electronics, Engineering, and Chemical.
ADM Tronics Unlimited (OTCQB: ADMT) reported a 27% increase in revenues for Q1 FY2023, totaling $921,408 compared to $721,358 in the prior year. Despite facing challenges from supply chain issues and increased raw material costs, the company maintained a 42% gross profit margin. R&D expenses decreased by 23%, reflecting the nearing completion of the Vet-Sonotron technology development. Loss from operations also improved, decreasing by 20% to $34,625. ADMT anticipates continued revenue growth.
ADM Tronics Unlimited, Inc. (OTCQB:ADMT) announced fiscal results for the year ending March 31, 2022, showing revenues of $3.21 million, a 4% increase from the prior year. Gross profit rose to $1.25 million, approximately 39% of revenues. Operating expenses increased to $2.38 million, leading to a net loss of $1.38 million. The company remains focused on the commercialization of its Vet-Sonotron technology despite ongoing supply chain issues. Positive future growth opportunities are anticipated from both Vet-Sonotron and the upcoming Sonotron Mark 2.
Aveta Life is collaborating with ADM Tronics Unlimited (OTCQB - ADMT) to develop the Hormonometer™, a new hormonal diagnostic platform. This innovative technology aims to enhance women's health through at-home hormonal monitoring. ADMT will provide regulatory guidance for the product to meet US FDA and CE certifications. CEO Andre’ DiMino will join Aveta Life's Advisory Board, contributing extensive experience in medical device development. The collaboration signals a significant step toward advancing women's health technology and ensuring compliance with regulatory standards.
FAQ
What is the current stock price of Adm Tronics (ADMT)?
What is the market cap of Adm Tronics (ADMT)?
